Get the Stockscreener App
15.29
0.39%
0.09
Rapport Therapeutics Inc stock is traded at $15.29, with a volume of 98,864.
It is up +0.39% in the last 24 hours and up +40.26% over the past month.
Rapport Therapeutics Inc is a clinical-stage biopharmaceutical company focused on discovery and development of transformational small-molecule medicines for patients suffering from central nervous system disorders. Its foundational science has elucidated the complexities of neuronal receptor biology and enables the company to map and target certain neuronal receptor complexes. Neuronal receptors are complex assemblies of proteins, comprising receptor principal subunits and their receptor-associated proteins (RAPs), the latter of which play crucial roles in regulating receptor expression and function.
See More
Previous Close:
$15.20
Open:
$15.2
24h Volume:
98,864
Relative Volume:
0.58
Market Cap:
$555.86M
Revenue:
-
Net Income/Loss:
-
P/E Ratio:
-
EPS:
-
Net Cash Flow:
-
1W Performance:
+0.26%
1M Performance:
+40.26%
6M Performance:
+6.94%
1Y Performance:
-25.01%
1-Day Range:
$14.86
$15.72
1-Week Range:
$14.10
$16.32
52-Week Range:
$7.13
$29.74
Rapport Therapeutics Inc Stock (RAPP) Company Profile
Name
Rapport Therapeutics Inc
Sector
Industry
Phone
857-321-8020
Address
1325 BOYLSTON STREET, BOSTON
Compare RAPP with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
RAPP
Rapport Therapeutics Inc
|
15.23 | 524.84M | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
477.94 | 119.21B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
576.25 | 59.16B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
327.85 | 40.57B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
570.44 | 34.02B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
295.05 | 29.19B | 3.81B | -644.79M | -669.77M | -6.24 |
Rapport Therapeutics Inc Stock (RAPP) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-08-25 | Initiated | Citizens JMP | Mkt Outperform |
| Jul-02-24 | Initiated | Jefferies | Buy |
| Jul-02-24 | Initiated | Stifel | Buy |
| Jul-02-24 | Initiated | TD Cowen | Buy |
Rapport Therapeutics Inc Stock (RAPP) Latest News
What analysts say about Rapport Therapeutics Inc. stockHigh-impact stock picks - Autocar Professional
Is Rapport Therapeutics Inc. a good long term investmentFree Stock Market Return Analysis - jammulinksnews.com
Rapport Therapeutics Inc. Stock Analysis and ForecastMarket-crushing stock picks - Autocar Professional
How the (RAPP) price action is used to our Advantage - news.stocktradersdaily.com
What drives Rapport Therapeutics Inc. stock priceExceptional profit potential - Jammu Links News
What drives EOSEW stock priceExceptional gains - Jammu Links News
Top Dividend Stocks in India Expert Trader GroupRapid wealth multiplication - Jammu Links News
What analysts say about Palvella Therapeutics Inc. stockAccelerated capital growth - jammulinksnews.com
What analysts say about Eaton Vance Municipal Income 2028 Term Trust stock outlookSecure Growth Trading Plan - Newser
why rapport therapeutics inc. stock attracts strong analyst attentionFree Exclusive Access to Stock Gurus - Newser
JMP reiterates Market Outperform rating on Rapport Therapeutics stock By Investing.com - Investing.com Canada
Why Rapport Therapeutics Inc. stock attracts strong analyst attentionShort Term Risk Controlled Alerts - Newser
What makes PTC Therapeutics Inc. stock price move sharplyTop Momentum Stock Pick - Newser
Rapport Therapeutics Reports Q1 2025 Financial Results - MSN
Why CRMD stock attracts strong analyst attentionAlpha Stock Ideas - Newser
How High Can MOON(moon coin) GoFree Wealth-Building Investment Strategies - Newser
How Rapport Therapeutics Inc. stock performs during market volatilitySmart Money Signals - Newser
Why Entegris Inc. stock attracts strong analyst attentionVerified Return Tips - Newser
Why Coya Therapeutics Inc. stock attracts strong analyst attentionFree Access to Group - Newser
What makes CIGI stock price move sharplyHigh Return Intraday Picks - Newser
What makes Rapport Therapeutics Inc. stock price move sharplyFree Insider Trading Tips - Newser
How American Water Works Company Inc. stock performs during market volatilityChart Breakout Alert - Newser
What makes IPCXU stock price move sharplyFree Group Entry - Newser
When CLEU stock expected to show significant growthIs SXTC stock a good long term investment optionTriple Return With Stability - Newser
Why SPHL stock attracts strong analyst attentionFree Stock Market Strategy Classes - Newser
Leverage AI to enhance your marketing strategy with real time consumer insightsHigh Return Setup Scanner - Newser
Why Did Rapport Therapeutics Plunge 15.68%? Regulatory Setbacks, Financial Strain - AInvest
Rapport Therapeutics’ (RAPP) Market Outperform Rating Reiterated at JMP Securities - Defense World
How will RAPP's Q1 2025 earnings forecast impact investors? - AInvest
Rapport Therapeutics, Inc.(NasdaqGM: RAPP) dropped from Russell Microcap Growth Index - MarketScreener
AI for Carbon Capture and StorageCapital Efficient Investment Tips - Newser
How To Trade (RAPP) - news.stocktradersdaily.com
GAMMA Investing LLC Purchases 9,198 Shares of Rapport Therapeutics (NASDAQ:RAPP) - Defense World
Bank of America Corp DE Sells 12,532 Shares of Rapport Therapeutics (NASDAQ:RAPP) - Defense World
California State Teachers Retirement System Purchases 7,886 Shares of Rapport Therapeutics (NASDAQ:RAPP) - Defense World
Rapport Therapeutics Inc Stock (RAPP) Financials Data
There is no financial data for Rapport Therapeutics Inc (RAPP). Check out other stocks for more information.
Revenue
Net Income
Cash Flow
EPS
Rapport Therapeutics Inc Stock (RAPP) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Bredt David | Chief Scientific Officer |
Jun 16 '25 |
Sale |
11.00 |
8,500 |
93,522 |
443,642 |
5.02%
0.40%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):